Studies from Hurwitz and Kabbinavar 2003 and 2004 first demonstrated that Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF) improved response rates and prolonged survival in patients with metastatic colorectal cancer (11, 12). The gene discussed is VEGFA; the disease is metastatic colorectal cancer.